• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prediction of outcome in first-episode schizophrenia.

作者信息

Lieberman J A

机构信息

Hillside Hospital, Glen Oaks, NY 11004.

出版信息

J Clin Psychiatry. 1993 Mar;54 Suppl:13-7.

PMID:8097192
Abstract

Prompt and efficient treatment of acute psychotic episodes combined with the prevention of relapses will limit the accrued morbidity of schizophrenia. However, the heterogeneity of schizophrenia makes it difficult to determine which individuals are most likely to relapse. There are three major potential biological predictors of schizophrenic relapse: (1) behavioral response to dopamine agonist stimulation, (2) the presence of tardive dyskinesia, and (3) increases in anterior pituitary hormones. Dopamine agonists and dopamine antagonist provocative tests, using a single dose of medication, can be used to predict outcome in stabilized schizophrenics undergoing maintenance drug therapy. These tests are indicators of increased dopamine activity, which potentially indicates a worse outcome. This article discusses behavioral response to psychostimulant tests and pituitary hormone levels, particularly growth hormone and prolactin response to dopamine antagonist stimulation. As predictors of outcome, these measures may be useful, clinically, when selecting neuroleptic maintenance schedules, dosage, or withdrawal strategies.

摘要

相似文献

1
Prediction of outcome in first-episode schizophrenia.
J Clin Psychiatry. 1993 Mar;54 Suppl:13-7.
2
Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia.
Neuropsychopharmacology. 1994 Oct;11(2):107-18. doi: 10.1038/npp.1994.40.
3
Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia.迟发性运动障碍中的淋巴细胞单胺氧化酶、血浆催乳素和生长激素
J Clin Psychiatry. 1981 Feb;42(2):75-7.
4
Associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated schizophrenics: relevance to supersensitivity psychosis.接受治疗的精神分裂症患者血浆催乳素水平、迟发性运动障碍和偏执之间的关联:与超敏性精神病的相关性
Psychopharmacol Bull. 1986;22(3):897-9.
5
Prediction of relapse in schizophrenia.
Arch Gen Psychiatry. 1987 Jul;44(7):597-603. doi: 10.1001/archpsyc.1987.01800190013002.
6
Dose response of prophylactic antipsychotics.预防性抗精神病药物的剂量反应。
J Clin Psychiatry. 1993 Mar;54 Suppl:24-30.
7
Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.帕利哌酮缓释片用于精神分裂症的急性和维持治疗。
Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011.
8
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.首发精神分裂症的长期药物治疗策略——德国精神分裂症研究网络中一项正在进行的随机对照试验的研究设计与初步结果
Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):129-40. doi: 10.1007/s00406-004-0509-y.
9
Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia.
Psychopharmacol Bull. 1990;26(2):224-30.
10
Aripiprazole: new drug. Just another neuroleptic.阿立哌唑:新药。不过是另一种抗精神病药。
Prescrire Int. 2005 Oct;14(79):163-7.

引用本文的文献

1
One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study.首发与复发精神分裂症的一年期结局:一项真实世界的自然主义研究。
Clin Psychopharmacol Neurosci. 2020 Aug 31;18(3):434-444. doi: 10.9758/cpn.2020.18.3.434.
2
Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View.难治性精神分裂症的临床病程、神经生物学及治疗方法。迈向综合观点。
Front Psychiatry. 2019 Sep 3;10:601. doi: 10.3389/fpsyt.2019.00601. eCollection 2019.
3
[The CIMH track concept in the treatment of psychotic disorders].
[精神疾病治疗中的CIMH轨迹概念]
Nervenarzt. 2020 Mar;91(3):233-242. doi: 10.1007/s00115-019-0711-9.
4
Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review.首发精神病治疗抵抗的预测因素:一项系统综述
Front Psychiatry. 2019 Feb 26;10:67. doi: 10.3389/fpsyt.2019.00067. eCollection 2019.
5
The promise of biological markers for treatment response in first-episode psychosis: a systematic review.首发精神病治疗反应生物标志物的前景:一项系统综述
Schizophr Bull. 2015 May;41(3):559-73. doi: 10.1093/schbul/sbv002. Epub 2015 Mar 10.
6
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.初发未用药的精神分裂症患者纹状体D(2/3)结合潜能值与治疗结果相关。
Schizophr Bull. 2015 Sep;41(5):1143-52. doi: 10.1093/schbul/sbu220. Epub 2015 Feb 18.
7
A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia.奥氮平与利培酮治疗精神分裂症的比较研究
Schizophr Res Treatment. 2014;2014:307202. doi: 10.1155/2014/307202. Epub 2014 Aug 26.
8
Integrated treatment to achieve functional recovery for first-episode psychosis.综合治疗以实现首发精神病的功能恢复。
Schizophr Res Treatment. 2012;2012:962371. doi: 10.1155/2012/962371. Epub 2012 May 10.
9
Pharmacogenetics of response to antipsychotics in patients with schizophrenia.精神分裂症患者对抗精神病药物反应的遗传药理学。
CNS Drugs. 2011 Nov 1;25(11):933-69. doi: 10.2165/11595380-000000000-00000.
10
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing.在执行加工过程中对超高危、早期及慢性精神分裂症患者的额纹状体功能进行成像。
Arch Gen Psychiatry. 2005 Mar;62(3):254-62. doi: 10.1001/archpsyc.62.3.254.